<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="4224"><DrugName>rHb1.1</DrugName><DrugNamesKey><Name id="42767075">Optro</Name></DrugNamesKey><DrugSynonyms><Name><Value>Optro</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>rHb1.1</Value></Name><Name><Value>hemoglobin, Somatogen</Value></Name></DrugSynonyms><CompanyOriginator id="16983">Somatogen Inc</CompanyOriginator><CompaniesSecondary><Company id="16983">Somatogen Inc</Company><Company id="17810">Eli Lilly &amp; Co</Company><Company id="22028">Kabi Pharmacia AB</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4224" type="Drug"><TargetEntity id="193832" type="siDrug">rHb1.1</TargetEntity></SourceEntity><SourceEntity id="16983" type="Company"><TargetEntity id="4295911462" type="organizationId">Somatogen Inc</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="22028" type="Company"><TargetEntity id="5035750204" type="organizationId">Kabi Pharmacia AB</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"></TargetEntity><TargetEntity id="D000740" type="MeSH"></TargetEntity><TargetEntity id="-201701473" type="omicsDisease"></TargetEntity><TargetEntity id="988" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="286" type="ciIndication"><TargetEntity id="10029151" type="MEDDRA"></TargetEntity><TargetEntity id="D007674" type="MeSH"></TargetEntity><TargetEntity id="-966472843" type="omicsDisease"></TargetEntity><TargetEntity id="334" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="552" type="ciIndication"><TargetEntity id="10055798" type="MEDDRA"></TargetEntity><TargetEntity id="D006470" type="MeSH"></TargetEntity><TargetEntity id="-1283225934" type="omicsDisease"></TargetEntity><TargetEntity id="327" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="17">Anemia</Indication><Indication id="286">Renal disease</Indication><Indication id="552">Bleeding</Indication></IndicationsSecondary><ActionsPrimary><Action id="474">Hemoglobin modulator</Action></ActionsPrimary><ActionsSecondary><Action id="5002">Blood substitute</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology></Technologies><EphmraCodes><Ephmra><Code>K3</Code><Name>WHOLE BLOOD AND PLASMA SUBSTITUTE SOLUTIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-30T10:35:57.000Z</LastModificationDate><ChangeDateLast>2009-04-07T13:55:18.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Baxter (formerly &lt;ulink linkID="16983" linkType="Company"&gt;Somatogen&lt;/ulink&gt;) was developing recombinant hemoglobin, rHb1.1, for the potential treatment of anemia and as a blood volume restorer. Other possible therapeutic applications under investigation included the treatment or prevention of tissue hypoxia observed in trauma, stroke and myocardial infarction [&lt;ulink linkID="281789" linkType="reference"&gt;281789&lt;/ulink&gt;]. The compound had entered phase II US trials for the treatment of anemia, and to restore blood volume after surgery [&lt;ulink linkID="213474" linkType="reference"&gt;213474&lt;/ulink&gt;]. The company was planning to expand the phase II trials in the US, Canada and Europe and phase III trials were expected to begin in late 1997. However no development had been reported since 1998 [&lt;ulink linkID="240545" linkType="reference"&gt;240545&lt;/ulink&gt;] and in April 2001, the company confirmed that development of rHb1.1 had been discontinued [&lt;ulink linkID="406662" linkType="reference"&gt;406662&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;There were considered to be no clinically significant, treatment-related adverse events in the early, phase II trials which were conducted to measure safety and efficacy of rHb1.1 [&lt;ulink linkID="175077" linkType="reference"&gt;175077&lt;/ulink&gt;]. The company has completed a dose-escalation trial in 23 patients requiring four units of blood following intraoperative (IO) blood loss. Six patients received a 25 g dose; four 50 g; three 75g and three 100 g. Control patients received standard transfusion therapy. None of the patients experienced gastrointestinal symptoms, however, in certain patients there was a transitory elevation of amylase and lipase levels, which spontaneously resolved without treatment, and which investigators determined not to be clinically significant [&lt;ulink linkID="221312" linkType="reference"&gt;221312&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A second dose-escalation trial, in ten patients who received up to 50 g, has been completed. The trial evaluated the use of rHb1.1 for acute normovolemic hemodilution (ANH) to maintain blood volume and oxygenation following the withdrawal of blood from patients for reinfusion after surgery. Control patients received normal saline. There were no clinically-significant treatment-related adverse events [&lt;ulink linkID="221312" linkType="reference"&gt;221312&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 1997, Somatogen began enrollment in a phase II trial of rHb1.1 in patients undergoing coronary bypass (CPB) during surgery. The randomized, double-blind trial was to study the ability of rHb1.1 to enhance the amount of autologous blood that can be withdrawn from a patient prior to surgery for reinfusion as needed during surgery, or following the bypass procedure in a technique known as acute normovolemic hemodilution (ANH). Endpoints will include avoidance or reduction in the amount of allogeneic blood products received by each patient [&lt;ulink linkID="244182" linkType="reference"&gt;244182&lt;/ulink&gt;]. Results from the first part of the trial, involving one and two unit dosing groups, were expected in late 1997 or early 1998. The second part of this study, with three and four unit groups, was expected to be completed in the first half of 1998 [&lt;ulink linkID="270937" linkType="reference"&gt;270937&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1996, Somatogen initiated patient enrollment (approximately 200 patients) in a multicenter, late phase II study of IO use of rHb1.1 to deliver oxygen and restore blood volume. The study was to examine the safety and efficacy of using between 25 and 100g doses in patients in the elective surgery setting. In previous trials, the maximum dose in safety studies was 25g [&lt;ulink linkID="221312" linkType="reference"&gt;221312&lt;/ulink&gt;]. By April 1997, the trial was discontinued after Lilly withdrew its support. At this time, Somatogen hoped to continue the program either by itself or with a new partner [&lt;ulink linkID="281374" linkType="reference"&gt;281374&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 1996, Somatogen initiated a phase I trial in approximately 50 patients with anemia resulting from end-stage renal disease (ESRD). The study was to evaluate the safety and hematopoietic activity of repeated low doses of rHb1.1 The trial was to be a dose-ranging study conducted at five sites in the US [&lt;ulink linkID="210151" linkType="reference"&gt;210151&lt;/ulink&gt;]. Results from the hematopoiesis trial were expected in the first quarter of 1998 [&lt;ulink linkID="270937" linkType="reference"&gt;270937&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;From 1991 to 1994, Somatogen conducted a series of clinical trials, initially in normal volunteers (phase I) and then in surgical patients (phase I/II) [&lt;ulink linkID="281789" linkType="reference"&gt;281789&lt;/ulink&gt;]. The recombinant hemoglobin was found to deliver oxygen to tissues as effectively as natural erythrocytes [&lt;ulink linkID="167505" linkType="reference"&gt;167505&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 1996, Somatogen received clearance from the US FDA to initiate clinical studies with rHb1.1 in patients with serious kidney disorders. In the trials, rHb1.1 was to be combined with Amgen's Epogam (gamolenic acid); in preliminary studies, the combination produced a synergistic effect. Following the completion of these trials (expected between 1998-2000) Somatogen was to seek FDA approval [&lt;ulink linkID="201496" linkType="reference"&gt;201496&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In future product generations, recombinant hemoglobin has potential for multiple indications, both as an oxygen-carrying therapeutic and as a pharmaceutical with other non-oxygen-related applications such as stimulation of erythropoiesis [&lt;ulink linkID="180689" linkType="reference"&gt;180689&lt;/ulink&gt;], [&lt;ulink linkID="189178" linkType="reference"&gt;189178&lt;/ulink&gt;]. It eliminates the risk of infectious disease transmission through being produced recombinantly, offers universal compatibility irrespective of blood type and improves upon the oxygen-delivering capability of hemoglobin in transfused red blood cells. Further, its use reduces dependency on blood from donors, has a longer shelf life and requires no chemical modifications to prevent it from fragmenting in the bloodstream [&lt;ulink linkID="180680" linkType="reference"&gt;180680&lt;/ulink&gt;]. Higher molecular weight hemoglobins were under investigation [&lt;ulink linkID="189188" linkType="reference"&gt;189188&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In June 1994, Lilly and Somatogen entered into a strategic sales and marketing agreement. Under the agreement, Lilly was to assume responsibility for commercial-scale manufacture of rHb1.1.1 and was to have exclusive marketing rights worldwide except in North America and Scandinavia. Lilly were to co-promote rHb1.1 with Somatogen in North America [&lt;ulink linkID="160472" linkType="reference"&gt;160472&lt;/ulink&gt;]. However in March 1997, Lilly discontinued its support for rHb1.1 under this collaborative agreement. At this time, Lilly expressed an interest in exploring the possibilities of restructuring the collaboration with respect to other indications of rHb1.1 and future generations of Somatogen's recombinant hemoglobin technology [&lt;ulink linkID="239666" linkType="reference"&gt;239666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 1991. &lt;ulink linkID="18937" linkType="Company"&gt;Pharmacia&lt;/ulink&gt; (formerly Kabi &lt;ulink linkID="18937" linkType="Company"&gt;Pharmacia&lt;/ulink&gt;) entered into a distribution agreement with Somatogen. Under the agreement, Kabi &lt;ulink linkID="18937" linkType="Company"&gt;Pharmacia&lt;/ulink&gt; was granted exclusive rights to market and distribute rHb1.1 in Scandinavia.&lt;/para&gt;&lt;para&gt;Somatogen had filed or licensed patent applications in the US and other countries for the recombinant hemoglobin technology and associated compounds. The initial US patent covering blood substitute or oxygen delivering products was issued in July 1991 and is due to expire in 2008 [&lt;ulink linkID="281789" linkType="reference"&gt;281789&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16983">Somatogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="552">Bleeding</Indication><StatusDate>2001-04-20T00:00:00.000Z</StatusDate><Source id="406662" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16983">Somatogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="286">Renal disease</Indication><StatusDate>2001-04-20T00:00:00.000Z</StatusDate><Source id="406662" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16983">Somatogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="17">Anemia</Indication><StatusDate>2001-04-20T00:00:00.000Z</StatusDate><Source id="406662" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="552">Bleeding</Indication><StatusDate>1997-04-07T00:00:00.000Z</StatusDate><Source id="241064" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22028">Kabi Pharmacia AB</Company><Country id="XP">Scandinavia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="17">Anemia</Indication><StatusDate>2001-04-20T00:00:00.000Z</StatusDate><Source id="406662" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="17">Anemia</Indication><StatusDate>1997-04-01T00:00:00.000Z</StatusDate><Source id="241064" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="16983">Somatogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2001-03-05T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16983">Somatogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="286">Renal disease</Indication><StatusDate>2001-03-05T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16983">Somatogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="552">Bleeding</Indication><StatusDate>2001-03-05T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16983">Somatogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="552">Bleeding</Indication><StatusDate>1996-07-01T00:00:00.000Z</StatusDate><Source id="213474" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16983">Somatogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="286">Renal disease</Indication><StatusDate>1996-06-12T00:00:00.000Z</StatusDate><Source id="210151" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16983">Somatogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="17">Anemia</Indication><Source id="171099" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22028">Kabi Pharmacia AB</Company><Country id="XP">Scandinavia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2001-03-05T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22028">Kabi Pharmacia AB</Company><Country id="XP">Scandinavia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="17">Anemia</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="552">Bleeding</Indication><StatusDate>1994-06-01T00:00:00.000Z</StatusDate><Source id="160472" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>1994-06-01T00:00:00.000Z</StatusDate><Source id="160472" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00905"><Name>Hemoglobin</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14437">Baxter International Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17810">Eli Lilly &amp; Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="117043" title="Eli Lilly to market Somatogen's rHb1.1 worldwide excluding North America and Scandinavia"/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>